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Néstor-Guillermo Progeria Syndrome: a
biochemical insight into Barrier-to-Autointegration
Factor 1, alanine 12 threonine mutation
Nicolas Paquet1†, Joseph K Box1†, Nicholas W Ashton1, Amila Suraweera1, Laura V Croft1, Aaron J Urquhart1,
Emma Bolderson1, Shu-Dong Zhang2, Kenneth J O’Byrne1 and Derek J Richard1*
Abstract
Background: Premature aging syndromes recapitulate many aspects of natural aging and provide an insight into
this phenomenon at a molecular and cellular level. The progeria syndromes appear to cause rapid aging through
disruption of normal nuclear structure. Recently, a coding mutation (c.34G > A [p.A12T]) in the Barrier to
Autointegration Factor 1 (BANF1) gene was identified as the genetic basis of Néstor-Guillermo Progeria syndrome
(NGPS). This mutation was described to cause instability in the BANF1 protein, causing a disruption of the nuclear
envelope structure.
Results: Here we demonstrate that the BANF1 A12T protein is indeed correctly folded, stable and that the
observed phenotype, is likely due to the disruption of the DNA binding surface of the A12T mutant. We
demonstrate, using biochemical assays, that the BANF1 A12T protein is impaired in its ability to bind DNA while its
interaction with nuclear envelope proteins is unperturbed. Consistent with this, we demonstrate that ectopic
expression of the mutant protein induces the NGPS cellular phenotype, while the protein localizes normally to the
nuclear envelope.
Conclusions: Our study clarifies the role of the A12T mutation in NGPS patients, which will be of importance for
understanding the development of the disease.
Keywords: Progeria, Nuclear envelope, Aging
Background
Aging is a natural process that affects all organisms, al-
though the precise mechanisms of its progression remain
poorly understood. As such, human premature aging syn-
dromes, which recapitulate many aspects of natural aging,
may allow us to further investigate this phenomenon at
the molecular and cellular level. These syndromes largely
result from heritable genetic alterations that mainly affect
DNA repair proteins, or proteins associated with the
nuclear periphery [1,2]. For instance, one category of pre-
mature aging syndromes, known as Human Progeroid
syndromes (or laminopathies), are caused by mutations in
nuclear lamins or other proteins of the nuclear envelope.
As a result, cells from these patients are characterized by
nuclear envelope dysfunction, altered nuclear activity, im-
paired structural dynamics and aberrant cell signaling [3].
These irregularities may manifest in premature aging, as
well as conditions such as neuropathy.
Recently, two unrelated patients who exhibited several
Hutchinson-Gilford Progeria syndrome-like phenotypes
were described [4,5]. These patients, however, did not
present with many of the symptoms common to those
with known human Progeroid syndromes. For instance,
neither patient showed signs of ischemia or atheroscler-
osis, both fundamental phenotypes of Hutchinson-Gilford
Progeria syndrome. Cognitive function was also identified
as normal in both patients. Moreover, the age of the pa-
tients studied was not consistent with the current under-
standing of known human Progeroid syndromes, with
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these patients being much older than the average life span
of progeroid patients. This condition was named Néstor–
Guillermo Progeria Syndrome (NGPS). Whole-genome
and exome sequencing of both affected patients identified
them as homozygous for a mutation in the Barrier-to-
Autointegration Factor 1 (BAF1 or BANF1) gene [5]. This
mutation (c.34G >A [p.Ala12Thr]) results in the expres-
sion of a BANF1 protein where alanine 12 is mutated to a
threonine residue.
BANF1 encodes a protein consisting of 89 amino acid
residues with a molecular weight of approximately
10 kDa [6]. Nuclear magnetic resonance and crystallo-
graphic studies have determined that BANF1 may form
a homodimer, which is the active state required to bind
chromatin [7,8]. During G1, S and G2 phases of the cell
cycle, BANF1 is known to predominantly associate with
the nuclear envelope, where it interacts with the Lamina
associated polypeptides Emerin-MAN1 (LEM) domain
of the nuclear scaffold proteins MAN1 [9], Emerin [10]
and LAP2 [11,12]. Here, BANF1 regulates organization
of the chromatin structure at the nuclear envelope by
condensing DNA via a looping mechanism [13], as well
as by binding histone H3 and histone linker H1.1 [14].
The interaction between BANF1, chromatin and protein
from the lamina is tightly regulated, allowing proper nu-
clear assembly and chromatin organization during cell
cycle progression [15,16]. In addition to these roles,
BANF1 has been proposed to regulate the transcription
of specific genes [17], to suppress the integration of ret-
roviruses within the genome [6,18,19], and to regulate
specific developmental signals [15,20].
Despite the available data on BANF1 biology, the con-
tribution of the A12T mutation to the development of
Nestor-Guillermo Progeria Syndrome is poorly under-
stood. In their original study of the disease, Puente et al.
observed reduced levels of mutant BANF1 in patient fi-
broblasts, and thus proposed that the mutation may
affect protein stability [5]. It was therefore assumed that
the observed phenotype of these patients was due to
physiologically low levels of BANF1 [5]. In the present
study, we aimed to further decipher the role of the
BANF1 A12T mutation in the molecular processes lead-
ing to the development of the disease. To do so, we used
a series of biochemical and molecular tools to under-
stand the defect resulting from this genetic mutation.
Results
In order to characterize the effect of the A12T mutation
on the BANF1 protein and NGPS phenotype, we initially
purified recombinant His-tagged BANF1 wild type (WT)
and A12T proteins from E. coli using a protocol adapted
from Harris et al. [19], although unlike Harris et al, we
retained the N-terminal His-tag. As previously described,
recombinant WT BANF1 was found in inclusion bodies
(as was the A12T mutant), indicating aggregation of the
protein in a higher-ordered complex, and thus necessitat-
ing denaturation and subsequent refolding of the protein
during purification. Using this method, both wild type
and A12T BANF1 displayed similar purification charac-
teristics (Figure 1A). BANF1 forms a stable dimer in so-
lution with a dimerization interface formed by helix α3,
the C-terminus of α5 and part of the loop linking α1 to
the helical turn [7]. Although alanine 12 is not located
at the dimerization interface of BANF1, we experimen-
tally tested whether A12T mutation may influence this
interface indirectly. To do this, we detected both mu-
tant and wild type protein as they eluted from a size ex-
clusion column (Figure 1B). Here, both wild type and
A12T recombinant BANF1 eluted with a profile con-
sistent with a mixture of monomeric and dimeric
BANF1, supporting that this mutation does not disrupt
the dimerization of the protein in vitro.
As alanine 12 of BANF1 is positioned in a loop imme-
diately following helix α1, we hypothesized that muta-
tion of this residue to a bulky β-branched threonine
could influence the structure of the BANF1 protein. To
assess this, we analyzed recombinant WT and A12T
BANF1 by circular dichroism (CD), a standard biophys-
ical technique used to study the secondary structure
content of proteins in solution. CD spectra of both wild
type and A12T BANF1 showed typical α-helical profiles,
with minima in the near far- UV at a wavelength of
220 nm (Figure 1C). By this method we detected a
spectrum for wild type BANF1 that was consistent with
published data [19]. Furthermore, overlay of the A12T
BANF1 spectrum indicated the secondary structure of
the protein was not affected as a result of mutation.
To explore whether A12T mutation may alter the
BANF1 structure on a smaller scale, we obtained the
crystal structure of wild type BANF1 bound to DNA
from the Protein Data Bank (PDB ID 2BZF), and used
Phyre2 [21] (http://www.sbg.bio.ic.ac.uk/~phyre2) to
predict the three-dimensional structure of BANF1 fol-
lowing A12T mutation. Modeling was subsequently con-
firmed using I-TASSER [22] (http://zhanglab.ccmb.med.
umich.edu/I-TASSER/). Consistent with the CD spectra
data, Phyre2 model prediction of the A12T mutant did
not suggest major modifications to the structure of
BANF1, although interestingly did indicate a potential
alteration in the position of amino acids essential for DNA
binding (Figure 2A). Based on the crystal structure, the N
terminus of BANF1 helix α1 is important for contacting
DNA and establishing hydrogen bonds between Gln5, Lys6
and the nucleotide phosphates [7]. In our model, we
therefore predict that the BANF1 A12T mutation may
displace the side chain of Lys6 from its original position
(Figure 2B), preventing the formation of hydrogen bonds
between this residue and the phosphodiester backbone
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and thus indicating a possible DNA binding defect. Inter-
estingly, Lys6 is also known to be buried in a pocket
formed by the carbonyl groups of Gly21, Ile26 and Leu23
[7]. In our prediction, the Lys6 ε-amino group sits outside
this pocket, which is likely to have structural and func-
tional consequences (Figure 2C). In addition, our model
also predicts the side chains of Glu13 are displaced, poten-
tially affecting the formation of the salt bridge between
this residue and Lys18 [23] (Figure 2D). Both Lys6 and
Glu13 are important for the stabilization of helix α1 and
the loop connecting α1 and α3, which brings positively
charged Lys6 and Arg8 to the DNA binding site.
To understand further the instability previously de-
scribed for A12T BANF1, we expressed 3x FLAG-tagged
WT or A12T BANF1 in HeLa cells from a CMV pro-
moter. Consistent with the observations of Puente et al.
Figure 1 Characterization of WT and A12T Barrier to Autointegration 1 proteins. (A): Coomassie blue staining of 500 ng of recombinant
wild type and A12T HexaHis-tagged BANF1 run on a Nu-Page gel. (B): Gel filtration chromatography of wild type and A12T mutant BANF1 proteins.
Absorbance at 280 nm was plotted against the elution volume. Both proteins eluted in two predominant peaks, which are consistent with dimeric and
monomeric BANF1. Vo indicates the void volume of the column and Vt indicates the termination volume. Arrows indicate the elution volume of the
protein standards carbonic anhydrase (29 kDa) and Myoglobin (17 kDa), which were used to calibrate the column prior to BANF1 filtration. (C): A12T
BANF1 secondary structure is not modified when compared to the WT. CD spectroscopy of wild-type and A12T BANF1 protein. The mean residue
ellipticity Δε of the indicated protein is plotted against the wavelength, and is the results of 3 independent measurements. Δε is in cm-1.M-1.
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[5], we observed minimal levels of the A12T mutant pro-
tein when compared to the wild type protein, as deter-
mined by immunoblotting using the same BANF1
antibody as in their study (Figure 3A). To confirm that we
had indeed detected ectopically expressed FLAG tagged
BANF1, we stripped the nitrocellulose membrane of the
BANF1 antibody and re-probed with an antibody against
the FLAG tag (Sigma, F1804 SL11063). Unexpectedly, this
indicated equal expression of both the wild type and mu-
tant BANF1.
These data raise the possibility that alanine 12 is re-
quired for antibody recognition of BANF1, such that re-
duced antigenicity may result from A12T mutation. To
test this further, 500 ng of recombinant BANF1 WT and
A12T was run on a SDS page gel and transferred to a
nitrocellulose membrane for immunoblotting (Figure 3B).
Figure 2 Structural model of the BANF1 A12T protein. (A-D): BANF A12T modeling predicts fine changes in the position of key amino acids.
WT and A12T sequences were used to generate a model using Phyre2 software. The resulting models were fitted on the existing crystal structure
of BANF1 bound to DNA (PDB: 2BZF). (A): Superposition of ribbon diagrams of monomeric WT (Blue) and A12T (gray) BANF1, indicating
modification of the loop connecting helix α1 and α3. (B): Ribbons diagrams of WT (Blue) and A12T (Gray) BANF1, indicating the hydrogen bonds
between Lys6 and Gln5 with DNA nucleotides d13 and d14 DNA (as depicted in PDB: 2BZF). Lys6’ and Gln5’ from BANF1 A12T are seen displaced
from their WT counterpart. (C): Ribbon diagrams of WT (Blue) and A12T (Gray) BANF1. Schematics indicate that in the WT, Lys6 protrudes into the
pocket formed by Gly21, Ile26 and Leu23. Lys6’ sits outside this pocket in the A12T mutant. (D): Ribbon diagrams of WT (Blue) and A12T (Gray)
BANF1, showing the salt bridge between Glu13 and Lys18 in the WT. Glu13’ and Lys18’ are displaced in the BANF1 A12T prediction.
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The loading of equal quantities of proteins was verified by
staining of the membrane using Ponceau red. The immu-
noblot was then probed using an anti-BANF1 antibody
(Abcam ab88464). Similar to our findings using overex-
pressed WT and A12T BANF1 in cells, the BANF1 anti-
body failed to recognize the A12T recombinant protein to
a level comparable to that observed for the wild type pro-
tein. To confirm this result, the membrane was stripped of
antibody and then re-probed using an anti-HexaHis anti-
body (Abcam ab1187) to detect the N-terminal His tag of
the recombinant BANF1 proteins. Consistent with the
Ponceau staining, the anti-HexaHis antibody demon-
strated that both proteins were present in similar
amounts (Figure 3B). In an attempt to confirm these
findings, further immunoblots using a BANF1 antibody
supplied by Sigma (SAB1404629) were performed, and
again the BANF1 antibody demonstrated a lack of recog-
nition of the mutant protein (Figure 3C). This experiment
was repeated several times with proteins from different
purification batches and consistently suggested a reduced
antigenicity of the mutant protein when anti-BANF1 anti-
body was used. Interestingly, a similar alteration of antige-
nicity of BANF1 as a result of epitope mutation has
previously been reported [18]. In this study by Lin and
Engelman, an anti-BANF1 antibody raised against a pep-
tide encompassing amino acids 4 to 20 did not recognize
K6A and K18A BANF1 mutant proteins. These findings
may be explained by the consideration that BANF1 is a
small and structured protein and that the antigenic re-
gions recognized by the antibody are likely to be com-
posed of only a few amino acids. The mutation of one of
these residues, or a residue impacting the structure of this
epitope, may therefore interfere with antibody binding.
The observation that A12T BANF1 may be of reduced
antigenicity compared to the wild type protein is of import-
ance, as using the same BANF1 antibody, Puente et al.
Figure 3 Alteration of BANF1 A12T antigenicity and stability. (A): The anti-BANF1 antibody (Abcam: ab88464) does not recognize exogenous
A12T BANF1 in cell lysates. Cell extracts of U2OS cells overexpressing WT or A12T 3x FLAG-tagged BANF1 or an empty vector (pCMV-AN-3DDK)
were resolved on a Nu-page gel and immunoblotted using an anti-BANF1 antibody. Membranes were stripped and immunoblotted using an
anti-FLAG antibody. A β-actin antibody was used as an internal protein loading control. (B): Recombinant A12T BANF1 has a lower antigenicity
than WT BANF1. 500 ng of recombinant HexaHis tagged WT and A12T BANF1 were run on a Nu-page gel and subsequently transferred to a
nitrocellulose membrane. The membrane was stained using Ponceau red as a loading control, then blotted with an anti-BANF1 antibody
(Abcam ab88464). After visualization, the membrane was stripped and immunoblotted using an anti HexaHis antibody. (C): Recombinant A12T
BANF1 has a lower antigenicity than WT BANF1. BANF1 was visualized by blotting with an anti-BANF1 antibody (SAB1404629). (D): Wild type and
A12T mutant 3x FLAG BANF1 protein stability. Cells were incubated with cycloheximide (50 μg/ml) for the indicated time periods and cell lysates
harvested for western blot analysis. Protein levels were assessed using anti-FLAG antibodies to detect FLAG- tagged BANF1 and anti-actin
antibodies for protein loading. MDM2 degradation is shown as a positive control for the cycloheximide treatment. (E): Quantification of (D). Band
signal intensity was quantified using ImageJ and standardized against the protein level a t = 0. Error bars represent the standard deviation (SD)
from at least three independent experiments.
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detected a lower signal for BANF1 in cells from NGPS pa-
tients [5]. The authors then discussed the possibility that
the pathology observed is due to a decrease in the stability
of BANF1 A12T. In light of their results however, the hy-
pothesis of a reduced half-life for A12T BANF1 may be in-
adequate. To investigate whether A12T BANF1 is indeed
unstable, we investigated whether the half-life of this pro-
tein is reduced in cells compared to the wild type. To do
this, we transfected HeLa cells with plasmids expressing 3x
FLAG-tagged WT or A12T BANF1 and then treated these
cells with cycloheximide to block transcription and subse-
quent protein synthesis. Cells were then harvested 18 and
26 hours post treatment, lysates were separated by SDS-
PAGE and proteins transferred to nitrocellulose. Ectopi-
cally expressed BANF1 was then detected by Western blot
analysis using the anti-FLAG antibody. As shown in
Figure 3D-E, similar decay patterns were detected for both
WT and A12T BANF1 over the experimental time course
(Figures 3D-E). These data demonstrate similar stability of
WT and A12T BANF1. To confirm efficacy of our treat-
ment, we also immunoblotted for MDM2, a protein with a
known short-life; as expected, loss of protein was observed
by our first time point [24]. We were unable to extend our
cycloheximide treatment past 26 hours due to cell death.
Taken together, our results provide strong evidence that
the BANF1 A12T mutant is stable and that the phenotype
seen in the NGPS patients is likely to be due to an altered
function of BANF1.
As mentioned previously, our structural modeling indi-
cated the presence of a bulky threonine residue, in place
of alanine residue 12, might disrupt the DNA binding
pocket of BANF1. To investigate this further, we per-
formed DNA mobility shift assays. Escalating concentra-
tions of recombinant purified WT and A12T BANF1 were
incubated with a 21 nucleotide double-stranded DNA
oligonucleotide. The DNA probe was labeled with a 5’
FAM and the interaction between BANF1 and the DNA
observed as retardation in the migration of the complex
through a polyacrylamide gel. As previously described,
BANF1 WT has a high affinity for double-stranded DNA
and bundles DNA in a highly ordered nucleoprotein com-
plex [25]. The kinetics of binding were first studied after
incubation for 5 minutes at 37°C, however due to the rate
of binding, we were unable to observe intermediate com-
plexes. The reaction was then performed at 4°C for 30 mi-
nutes and this allowed us to observe the lower order
complexes. Interestingly, the BANF1 A12T mutant exhib-
ited a marked defect in DNA binding compared to the
wild type protein (Figure 4A,B). To confirm our observa-
tion we conducted DNA mobility shift assay in the same
conditions using a 4.5 kb double stranded DNA plasmid.
Consistent with our previous observations, A12T BANF1
exhibited a decreased affinity for longer DNA substrates
(Figure 4C).
Several other mutations have been reported to affect the
DNA binding properties of BANF1 [19,23,26]. They can
be classified based on the severity of the binding defect, as
well as their ability to dimerize and to bind Lamina-
associated proteins [20,26]. However, to date, none of
these mutants have solely impacted DNA binding versus
defects in protein binding. To determine if the A12T mu-
tation also affects the association with known nuclear en-
velope proteins, we performed co-immunoprecipitation
experiments. For this, 3x FLAG tagged wild type or A12T
BANF1 was expressed and immunoprecipitated in HeLa
cells. Immunoblotting was then performed using anti-
bodies against Emerin, Lamin and Histone H3, proteins
that have previously been shown to interact with BANF1
at the nuclear envelope [10-12,14]. Interestingly, BANF1
A12T did not display any defects in binding to these pro-
teins (Figure 4D). Interestingly, BANF1 A12T was still
present in the chromatin fraction of a subcellular fraction-
ation, consistent with its interaction with histone protein
H3 (Figure 4E). Consistent with these observations, im-
munofluorescence demonstrated that the A12T mutant
BANF1 localized normally to the nuclear envelope in
U2OS cells. Interestingly, although expression levels of
mutant and wild type were equivalent (as determined by
immunoblotting with the FLAG antibody), the majority of
cells expressing the A12T mutant demonstrated nuclear
envelope aberrations consistent with that observed in
NGPS patients (Figure 5A,B,C). Together, our data indi-
cates that the A12T mutation of BANF1, found in Nestor-
Guillermo Progeria syndrome, causes a disruption of the
DNA binding surface, inhibiting its normal interaction
with double stranded DNA. The BANF1 A12T mutant
however localizes normally to the nuclear envelope, where
it interacts with nuclear envelope proteins and chromatin.
Discussion
The identification of two Progeria individuals with a single
point mutation in BANF1 is important for our under-
standing of these syndromes. Interestingly, Puente et al.
reported that although mRNA levels of A12T mutant
BANF1 were found at similar levels to wild type patients,
BANF1 A12T protein was detected at a much lower level.
This was originally interpreted as a result of protein in-
stability. In our study, we sought to understand the mech-
anism through which this may occur. Interestingly, our
study suggested that the A12T mutant was not unstable,
and that the lower levels of the protein observed were
merely an artifact of antigenicity alterations towards the
BANF1 antibody, as a result of the A12T mutation. We
therefore reasoned that this mutation might affect protein
function in other ways that could explain the NGPS
phenotype. Our structural modeling of BANF1, predicted
that the mutation of alanine 12 to a bulky threonine, could
disrupt the BANF1 DNA-binding pocket and thus disrupt
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the interaction of BANF1 with DNA. We confirmed by
EMSA that the A12T BANF1 was indeed perturbed in its
ability to bind to DNA, suggesting that the modeling was
correct. Further, our modeling and CD spectra analysis
suggested that this was the only disruption to the BANF1
structure. Moreover, we found that the A12T mutant, like
WT BANF1, localized to the nuclear envelope and inter-
acted with lamin and histone H3. Further studies using
Figure 4 Alteration of BANF1 A12T DNA binding. (A): A12T BANF1 has a reduced affinity for short double-stranded DNA. WT and A12T BANF1
(0, 0.1, 0.25, 0.5, 0.75, 1, μM) was incubated for 30 min at 4°C with 10 nM of dsDNA that was labeled with a 5’ FAM label. The FAM label was
visualized using a Starion FLA-9000 image scanner. (B): Quantification of (A). Intensity of the signal was quantified using MultiGauge software
(Fujifilm). Error bars represent the standard deviation (SD) from at least three independent experiments. (C): A12T BANF1 has a reduced affinity for
long double-stranded DNA. WT and A12T BANF1 (0, 0.1, 0.25, 0.5, 1, 2 and 4 μM) was incubated for 30 min at 4°C with 150 ng of double stranded
DNA plasmid. The binding was visualized on an agarose gel following staining with Ethidium bromide. (D): The interaction between WT or A12T
BANF1 and known partners was tested by co-immunoprecipitation. HeLa cells were transfected with the indicated vectors and exogenous protein
expressed for 24 hours Total protein was then extracted and treated with Benzonase to degrade genomic DNA. M2 magnetic FLAG beads were used
to immunoprecipitate 3x FLAG BANF1 and eluent probed using specific antibodies against Lamin, Emerin and Histone H3. (E): A12T BANF1 nuclear
distribution is similar to that of WT BANF1. HeLa cells were transiently transfected with the indicated vectors prior to sub-cellular fractionation. Western
blotting of fractions was performed using an anti-FLAG antibody (to detect exogenous BANF1), anti-H3 (chromatin fraction loading control) and
anti-nucleolin (soluble nuclear loading control). *Bleed-through from antiH3 channel.
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Figure 5 Nuclear envelope localization of the BANF1 A12T protein. (A): A12T BANF1 localization to the nuclear envelope is unaltered from
the WT protein. U2OS cells were transfected with constructs expressing WT or A12T 3x FLAG BANF1. Soluble proteins were extracted with
detergent and cells permeabilised. BANF1 distribution was analyzed by immunofluorescence using an anti-FLAG antibody and a Deltavision PDV
microscope. Aberrant nuclear envelope conformation can be seen in cells expressing A12T BANF1. Emerin visualization is representative of the
nuclear membrane. (B): Quantification of the aberrant nuclei seen in the BANF1 A12T overexpression. (C): Immunoblot showing the expression
levels of FLAG-tagged BANF1 WT and A12T in comparison to BANF1 endogenous levels.
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nuclear magnetic resonance (NMR) or crystallographic
methods would be needed to gain a more detailed
visualization of A12T structural modulations.
Although we cannot exclude that the NGPS pheno-
types result from an undiscovered role of BANF1, we
suggest that the DNA binding deficiency observed in the
BANF1 A12T mutant contributes to the cellular pheno-
types observed in NGPS. BANF1 has many proposed
roles within the cell that requires it to bind to DNA.
BANF1 has been shown to simultaneously bind to the
nuclear membrane, LEM domain containing protein,
LAP2 and DNA in vitro, implicating BANF1 as having a
crucial role in tethering the chromatin to the nuclear en-
velope (12). Supporting this, both LAP2 and another
LEM-domain, BANF1-interacting protein, Emerin, inter-
act with other major structural components of the nuclear
envelope called Lamins. Lamins play a key role in nuclear
structure and assembly and mutations in Lamin genes also
lead to a human progeria syndrome, Hutchinson–Gilford
Progeria Syndrome (HGPS)(2). In HGPS the disruption
to the lamina organization, induced by the mutant
Lamin proteins leads to areas of weakness around the
nuclear envelope, this can cause the chromatin to her-
niate, pushing out the destabilized membrane. Interest-
ingly, while we were unable to assess NGPS patient
cells endogenously expressing mutant BANF1, ectopic
expression of the A12T BANF1 did result in herniation
of the nuclear envelope, consistent with what has been
reported for the patients ((5) Figure 5). It has been pro-
posed that BANF1, through direct binding to LEM
proteins and indirect binding to Lamins, may link chro-
matin to the inner nuclear envelope and this appears to
be the case in C. elegans (15). In support of this, herein
we have shown that mutation of A12T in BANF1 dis-
rupts the DNA binding of BANF1, leading to the dis-
ruption of the nuclear envelope.
Conclusions
Our study now clarifies the role of the BANF1 A12T
mutation in NGPS, providing insight into the disease
process. Our study has important implications for the
treatment of NGPS patients and has provided new
mechanistic insights into the function of BANF1 and the
nuclear envelope in aging.
Methods
Ethics approval
All experimental procedures are approved by the Institu-
tional Biosafety Sub-Committee of the University of
Queensland, Brisbane, Australia.
Plasmids
A pCMV6-AN-3DDK vector containing the BANF1 CDS
cloned into the AsiSI and MluI restriction sites was
purchased from Origene. The BANF1 CDS was further
sub-cloned into pEX-N-His (Origene) using the AsiSI and
MluI restriction sites. Enzymes were purchased from New
England Biolabs.
A12T mutations were introduced into both BANF1 vec-
tors by site-directed mutagenesis, using the primers A12T
F: CCGAGACTTCGTGACAGAGCCCA, and A12T R:
CCATGGGCTCTGTCACGAAGTCT. PCR was con-
ducted as per: AccuPrime Pfx polymerase (0.02 U.μl-1; Life
Technologies), 1x AccuPrime Pfx polymerase reaction
mix (Life Technologies), primers (0.3 μM) and template
(0.8 ng.μl-1), then cycling 19x at: 94°C (20 s), 57°C
(30 s), 68°C (6 min 30 s). This was followed by Dpn1
(New England Biolabs) digestion (0.8 U.μl-1, 2 h, 37°C)
and transformation by heat-shock into chemically compe-
tent α-select E. coli (Bioline). Successful mutagenesis was
confirmed by DNA sequencing (Australian Genome Re-
search Facility) using the primer VP1.5: GGACTTTCCAA
AATGTCG. Primers were purchased from Sigma-Aldrich.
BANF1 purification
Plasmids expressing HexaHis-tagged WT or A12T BANF1
were transformed into BL21 (DE3) pLys E. coli. Cells were
grown at 37°C and protein expression induced with 1 mM
IPTG. E. coli were harvested 3 h after induction by centri-
fugation and stored overnight at -80°C. Cell pellet was re-
suspended in 8 mL of lysis buffer (25 mM HEPES pH 7.5,
150 mM NaCl) per g of cells, and sonicated. Cell lysates
were centrifuged for 30 min at 17,00 rpm and the super-
natant discarded. The pellet fraction containing HexaHis
BANF1 was solubilized in buffer (25 mM HEPES pH 7.5,
150 mM NaCl, 25 mM imidazole) containing 6 M guanidi-
nium chloride, and kept under agitation for 1 h at 4°C. The
lysate was then further centrifuged and the clarified super-
natant incubated with HIS-Select® Nickel Affinity Gel for
2 h at 4°C, under agitation. The affinity gel was extensively
washed with the solubilization buffer and the protein was
eluted from the beads in buffer K (20 mM KH2PO4,
pH 7.4, 0.5 mM EDTA, 10% glycerol, 0.01% IGEPAL) com-
plemented with 300 mM KCl and 250 mM Imidazole. Elu-
ents were supplemented with 100 mM DTT and incubated
for 2 h at 40°C to reduce any remaining disulfide bonds.
Protein was then concentrated on a 10 kDa cut-off
Microsep™ centrifugal device (Pall corporation) to a vol-
ume of 250 μL and loaded on a Superose 6 10/300 GL size
exclusion chromatography column (GE healthcare) run
with K buffer containing 300 mM KCl. High molecular
weight fractions containing BANF1 were discarded and
fractions containing monomeric BANF1 at near homogen-
eity pooled, concentrated and stored at -80°C.
Protein model
Amino acids sequences from BANF1 WT and A12T were
used to generate three-dimensional model with Phyre2
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(http://www.sbg.bio.ic.ac.uk/~phyre2). Modeling was sub-
sequently confirmed using I-TASSER (http://zhanglab.
ccmb.med.umich.edu/I-TASSER/). Models generated were
visualized and analyzed using Swiss PDB viewer [27].
Cell lines
U20S and HeLa cells were cultured in RPMI 1640
medium (Sigma-Aldrich) containing 10% FCS and main-
tained in a humidified incubator at 37°C/5% CO2.
Transfection of FLAG-tagged Banf1 constructs
U2OS and HeLa cells were transfected with pCMV6-AN-
3DDK, WT or A12T 3x FLAG-tagged BANF1 constructs
using Lipofectamine™ 2000 (Invitrogen) as described by
the manufacturer. Expression of the 3x FLAG-tagged
BANF1 constructs was determined 24 h post-transfection
by immunoblotting with an anti-FLAG antibody. Cellular
fractionation and immunofluorescence was also carried
out 24 hours post transfection.
Antibodies
Primary antibodies used are as follows: ant-BANF1
(Abcam: ab88464, monoclonal, Sigma: SAB1404629,
monoclonal), anti-HexaHis (Abcam ab1187), anti-FLAG
M2 (Sigma, F3165), anti-Histone H3 (Cell Signaling,
9715), anti-nucleolin (Cell Signaling, 12247S) and anti-
Emerin (Cell Signaling, 5430S). Fluorescent secondary
antibodies used are: Donkey anti-Mouse 800 nm (LiCor;
IRDye 800CW 926-32212), Donkey anti-Rabbit (LiCor;
IRDye 680LT 926-28023) and Alexa Fluor 488 and 594
(Molecular Probes).
Cycloheximide block
HeLa cells were seeded in 6 cm dishes (300, 000 cells
per dish) and the following day transfections were car-
ried out using Lipofectamine 2000 as per the manufac-
turers instructions using 2 μg plasmid DNA per dish.
Cycloheximide (Sigma-Aldrich) was added to the dishes
24 h post transfection at a final concentration of 50 μg/
ml and cells were incubated for the indicated amount of
time. For the t = 0 h time point, cells were harvested im-
mediately after addition of cycloheximide.
Cellular fractionation
Cells were separated into cytoplasmic, membrane bound,
soluble nuclear, chromatin and cytoskeletal fractions using
the Subcellular Protein Fractionation Kit for cultured cells
(Thermo Scientific), according to the manufacturer’s in-
structions. Protein concentrations were estimated using a
Bicinchoninic acid assay (Sigma) and subsequently 10 μg
of the soluble nuclear and chromatin fractions were sepa-
rated on a 4-12% SDS-PAGE gel (Invitrogen) and immu-
noblotted with the indicated antibodies.
Western blot
Proteins were resolved on 4-12% gradient Nu-PAGE gels
(Life Technologies) and transferred to nitrocellulose
membrane. Membranes were blocked in 2% v/v fish gel-
atin (Sigma) in PBS-T for 30 min and incubated with the
anti BANF1 antibody diluted in 1% fish gelatin in PBS-T
overnight at 4°C. Membranes were washed in PBS-T, in-
cubated with secondary antibodies (LiCor) and scanned
on an Odyssey infrared imaging system (LiCor). Where
necessary, membranes were stripped using a mild strip-
ping buffer (15 g L-1 glycine pH 2.2, 1 g L-1 SDS, 1%
Tween20) and reprobed with the appropriate antibodies.
Synthetic DNA substrates
All oligonucleotides were purchased from Integrated
DNA Technology (IDT), forward: 5’FAM (carboxyfluo-
rescein) - CTCTCCCTTCGCTCCTTTCCTCT, reverse:
AGAGGAAAGGAGCGAAGGGAGAG.
All nucleotides were purified on 12% polyacrylamide,
7 M urea gels prior to further use. For dsDNA anneal-
ing, equimolar amounts of corresponding oligonucleo-
tides were mixed in annealing buffer (50 mM Tris
pH 7.5, 100 mM NaCl, 10 mM MgCl2), heated at 95°C
for 10 minutes and slowly cooled to room temperature.
The substrates were then purified on native 10% poly-
acrylamide gels.
Concentrations were determined using the OD260 and
the molar extinction coefficient of the oligonucleotides
(with εfluoresceine = 13,700 L/mol.cm).
Electrophoretic mobility shift assay
Reaction were carried out in 10 μL of buffer (10 mM
Tris HCl pH 7.0, 20 mM NaCl, 100 ng/mL BSA, 5 mM
DTT) with 10 nM of FAM labeled DNA duplex with
various concentration of WT or A12T HexaHis BANF1.
Proteins and DNA were incubated for 30 min at 4°C. Re-
actions were resolved on 7% polyacrylamide gels in 0.5x
TBE buffer run at 4°C for 90 min at 90 V.
Gels were scanned using a Starion FLA-9000 image
scanner (Fujifilm) and quantified using MultiGauge soft-
ware (Fujifilm).
Long substrate assays were performed in 10 μL of buf-
fer with 150 ng of empty pEX-N-His (Origene) with
various concentration of WT or A12T HexaHis BANF1.
Proteins and DNA were incubated for 30 min at 4°C. Re-
actions were resolved on 0.6% agarose gels in 1x TBE
running buffer and post stained using Ethidium brom-
ide. Images were taken using Bio-Rad’s Gel Doc system.
Immunofluorescence
U20S cells were seeded the day prior to transfection
with the 3x FLAG-tagged BANF1 constructs. Following
transfection, the cells were grown for 24 h and were sub-
sequently treated for 5 min on ice with extraction buffer
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(20 mM Hepes, 20 mM NaCl, 5 mM MgCl2, 1 mM ATP,
0.1 mM sodium orthovanadate, 1 mM sodium fluoride,
protease inhibitor cocktail (Roche), 0.5% IGEPAL (same
chemically as obsolete Nonidet P-40), pH 7.5), to remove
the soluble proteins. The cells were then fixed with 4%
paraformaldehyde and subsequently permeabilized with
0.2% Triton-X for 5 min and then blocked with 3% BSA
for 1 h. Cells were then incubated with the indicated pri-
mary antibodies for 1 h hour at RT, washed and counter-
stained with the corresponding Alexa Fluor conjugated
secondary antibodies for 1 h at RT. DNA was counter-
stained with DAP1 (Sigma, D9564). Images were captured
using a DeltaVision deconvolution microscope and the
figures were assembled using Adobe Photoshop CS6.
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